JPRN-jRCTa030200053招募中1 期
Exploratory study of adipose-derived mesenchymal stem cell line-derived platelet like cells (ASCL-PLC) in patients with refractory chronic skin ulcer - Exploratory study of ASCL-PLC
Obara Hideaki0 个研究点目标入组 10 人开始时间: 2020年6月18日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 85age old（—）
- 性别
- All
入选标准
- •Patients who participate in the study must meet all the criteria shown below.
- •1) Between the ages of 20 and 85 (at the time of consent), regardless of their sex.
- •2) Providing written consent.
- •3) Being able to be followed up, and willing to adhere to the protocol related to the following-up.
- •4) Having three or fewer refractory chronic skin ulcers of the targeted limb, with the total area ranging from 0.1 cm^2 to 10 cm^2. (The shortest diameter of one ulcer site should be at least 1 mm.)
- •5) Having received or receiving standard therapy performed at Keio University Hospital, or being treated at other medical institutions with a full-time cardiovascular surgeon (Standard therapy includes local ointment, systemic medication, endovascular treatment or bypass surgery for ischemic ulcers; ointment or compression therapy for venous stasis ulcers).
- •6) Patients who ulcer area at screening is documented and ulcers with less than 50% improvement after 1 month of standard therapy performed at Keio University Hospital, or treatment performed at at other medical institutions with a full-time cardiovascular surgeon.
排除标准
- •Patients who satisfy any of the criteria shown below will be excluded in the study.
- •1) With the value of SPP in the proximal margin of the targeted ulcer being 20 mm Hg or lower.
- •2) Having received trafermin or alprostadil alfadex within the last 7 days before the initiation of the treatment.
- •3) Continuously receiving immunosuppressive therapy including corticosteroids with poorly controlled underlying disease and unstable medical status (the receiving immunosuppressive therapy without dosage increase for at least one month prior to treatment is considered to be stable for the underlying disease. except for ointment, eye drops, and short-term use for asthma).
- •4) Receiving hemodialysis.
- •5) Having severe liver dysfunction, renal impairment, cardiovascular diseases, lung diseases, hematological diseases or metabolic diseases and considered to be inappropriate for the study by a lead investigator or other investigators.
- •6) Having diabetes with the value of HbA1c being 9.0% or higher, even after the medication.
- •7) Having developed acute myocardial infarction or cerebrovascular disease within the last 30 days before the initiation of the treatment.
- •8) Having cancer, or having been diagnosed with advanced cancer within 5 years before the case enrollment.
- •9) Breastfeeding, being pregnant, or could be pregnant. Patient who hopes to bear child, or who could not keep contraception.
- •10) Being enrolled in other clinical studies which aim for the treatment.
- •11) Having mental disorder or psychiatric symptoms, and considered to be inappropriate for the study.
- •12) Having a history of severe allergic reaction caused by the administration of cell therapy including blood transfusion.
- •13) Having an allergy to animals (cattle).
- •14) Having an allergy to streptomycin sulfate, amphotericin B, or penicillin.
- •15) Considered to be inappropriate for the study for various reasons by the lead investigator or other investigators.
- •16) Having an ulcer with an uncontrollable infection which needs antibiotics administration (Grade 2 or higher). (Prophylactic antibiotics are excluded. )
研究者
相似试验
招募中
1 期
The effect of fat-derived stem cells in treatment of multiple sclerosismultiple sclerosis.Demyelinating diseases of the central nervous system, multiple sclerosisG35-G37IRCT20091127002778N1Mashhad University of Medical Sciences10
已完成
不适用
Evaluation of mesenchymal stem cells for the treatment of lower back paiower Back PainLower Back PainMusculoskeletal - Other muscular and skeletal disordersACTRN12617000636358Magellan Stem Cells10
招募中
不适用
The evaluation of mesenchymal stem cells in the treatment of arthritisArthritisACTRN12617000638336Melbourne Stem Cell Centre200
进行中（未招募）
1 期
Cutaneous analysis after cells from adipose tissue applied in human face20 Health patients presenting photo aged skinG13.750.829.826RBR-2nn9y2universidade federal do rio de janeiro
已完成
不适用
se of stem cells in treatment of lung injuryAirway damage in chemical injuries.Chronic respiratory conditions due to chemicals, gases, fumes and vapoursIRCT2015110524890N1Veterans Foundation10